Rama D. Jager, M.D., M.B.A., F.A.C.S., University Retina & Macular Associates
University Retina and Macular Associates
Rama D. Jager, M.D., M.B.A., F.A.C.S., is a board-certified ophthalmologist and vitreoretinal surgeon. He is the President and Managing Partner of University Retina. He also serves as Clinical Professor of Ophthalmology at the University of Illinois at Chicago / Illinois Eye and Ear Infirmary.
Dr. Jager specializes in the medical and surgical diseases of the retina, vitreous, and macula, including age-related macular degeneration, retinal vascular occlusions, diabetic retinopathy, retinal detachment surgery, macular hole surgery, diabetic surgery, and epiretinal membrane surgery. He is also one of the few retina specialists worldwide trained to use the NAVILAS computer-navigated retinal imaging and laser treatment system.
Dr. Jager has authored over 60 scientific papers, book chapters, and national meeting presentations with published abstracts. He has also co-authored three books in ophthalmology, Age-Related Macular Degeneration: A Comprehensive Text and the third and fourth editions of the Massachusetts Eye & Ear Review Manual for Ophthalmology.
Dr. Jager is board certified by the American Board of Ophthalmology (recertified in 2014) and is a Fellow of the American Academy of Ophthalmology and a Fellow of the American College of Surgeons. He is also an active member of the American Society of Retina Specialists, the American Medical Association, and the Illinois Society of Eye Physicians and Surgeons.
Dr. Jager has made charitable care for the disadvantaged one of his lifelong missions. He has volunteered his professional time and organized medical mission trips to Africa, India, New Orleans, and co-founded the CURE Network (Collaborative Underserved Relief and Education) whose mission is to provide health care for the disadvantaged. More information about the CURE Network can be found at curenetwork.org. Dr. Jager cares for patients at University Retina headquarters in Oak Forest, Illinois. He is dedicated to the surgical teaching and mentoring of vitreoretinal fellows, residents, and medical students and new physicians, and has received awards for excellence in teaching.
Vitreoretinal Fellowship
- Harvard Medical School / Joslin Diabetes Center (ADA)
Ophthalmology Residency
- University of Chicago
Medical School
- Northwestern University Medical School
Business School
- Stanford University Graduate School of Business
Undergraduate
- Northwestern University, Biomedical Engineering
High School
- High School: Marist High School, Chicago, IL (Valedictorian)
Awards and Publications
Publications
Wang AL, Rao VR, Chen JJ, Lussier YA, Rehman J, Huang Y, Jager RD, Grassi MA. Role of FAM18B in diabetic retinopathy.
Mol Vis. 2014 Aug 4;20:1146-59.
Chedid EH, Golden QR, Jager RD. Operational challenges in delivery of a charity care program for diabetic retinopathy screening in an urban setting.
Perm J. 2013 Winter;17(1):21-5. doi: 10.7812/TPP/12-041.
Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.
Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.
Retina. 2010 Nov-Dec;30(10):1573-8.
Gabrielian A., Hariprasad S., Jager R., Green J., Mieler W. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.
Eye (Lond). 2010 Jan;24(1):29-35. Epub 2009 Mar 27.
Jager R., Mieler W., Miller J. Age-related Macular Degeneration.
New England Journal of Medicine. 2008 Jun 12;358(24):2606-17.
Benevento J., Jager R., Noble A., Latkany P., Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
Arch Ophthalmol. 2008 Aug;126(8):1152-6.
Mazzulla D., Hariprasad S., Jager R., Mieler W. Short-Term intraocular pressure trends after intravitreal injection of bevacizumab (Avastin). Retinal Cases & Brief Reports.
(Accepted 13 December 2007, and Article in Press)
Mojica, G., Hariprasad, S., Jager R., Mieler, W. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
British Journal of Ophthalmology. 2008 Apr;92(4):584.
Hariprasad S., Mieler W., Grassi M., Green J., Jager R., Miller L. Vision-related quality of life in patients with diabetic macular oedema.
British Journal of Ophthalmology. 2008 Jan;92(1):89-92. Epub 2007 Jun 21.
Shukla D., Aiello L., Kolluru C., Baddela S., Jager R., Kim R. Relation of optical coherence tomography and unusual angiographic leakage patterns in central serous chorioretinopathy.
Eye. 2007 Apr 20.
Shukla D., Dhoble P., Jager R., Aiello L.P., Ramasamy K. Closure of macular hole following vitrectomy for diabetic tractional macular detachment.
Eye. 2006 Dec;20(12):1386-8.
Singh, R., Jager, R., Alfaro, V., Puliafito, C. The Use of Optical Coherence Tomography in the Diagnosis and Assessment of AMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.
Wirostko, W., Jager, R., Singh, R., Kiernan, D., Mieler, W. Intraocular Foreign Bodies.
In Modern Management of Ocular Trauma, 2006.
Alfaro, D., Loethen, M., Jager, R., Kim, R. Ranibizumab (Lucentis™) for ARMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.
Agurto-Rivera R., Diaz-Rubio J., Torres-Bernal L., Macky T., Colina-Luquez J., Papa-Oliva G., Jager R,, Martinez-Jardon S., Fromow-Guerra J., Quiroz-Mercado H. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study.
BMC Ophthalmology. 2005 Nov 25;5:27.
Jager, R., Timothy, N., Coney, J., Katalinic, P., Cavicchi, R., Cavallerano, J., Aiello, L. Congenital Retinal Macrovessel.
Retina. 2005 Jun;25(4):538-540.
Jager R., Aiello, L., Patel S., Cunningham, E. Risks of Intravitreous Injection: A Comprehensive Review.
Retina. 2004 Oct;24(5):676-98.
Shahinian, L., Jain, S., Jager, R., et al. Dilute Topical Proparacaine for Pain Relief after Photorefractive Keratectomy.
Ophthalmology 1997; 104: 1327-1332.
Heymann, J., Jager, R., Subramaniam, S. Expression of Bacteriorhodopsin in Sf9 and COS-1 Cells.
Journal of Biomembranes and Bioenergetics 1997; 29: 55-59.
Jager, R., Chen, F. Musculoskeletal Photodiagnosis: Hereditary Multiple Exostoses.
Journal of Musculoskeletal Medicine 1998; 15(6): 63-64.
Chapters
Wang AL, Rao VR, Chen JJ, Lussier YA, Rehman J, Huang Y, Jager RD, Grassi MA. Role of FAM18B in diabetic retinopathy.
Mol Vis. 2014 Aug 4;20:1146-59.
Chedid EH, Golden QR, Jager RD. Operational challenges in delivery of a charity care program for diabetic retinopathy screening in an urban setting.
Perm J. 2013 Winter;17(1):21-5. doi: 10.7812/TPP/12-041.
Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.
Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.
Retina. 2010 Nov-Dec;30(10):1573-8.
Gabrielian A., Hariprasad S., Jager R., Green J., Mieler W. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.
Eye (Lond). 2010 Jan;24(1):29-35. Epub 2009 Mar 27.
Jager R., Mieler W., Miller J. Age-related Macular Degeneration.
New England Journal of Medicine. 2008 Jun 12;358(24):2606-17.
Benevento J., Jager R., Noble A., Latkany P., Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
Arch Ophthalmol. 2008 Aug;126(8):1152-6.
Mazzulla D., Hariprasad S., Jager R., Mieler W. Short-Term intraocular pressure trends after intravitreal injection of bevacizumab (Avastin). Retinal Cases & Brief Reports.
(Accepted 13 December 2007, and Article in Press)
Mojica, G., Hariprasad, S., Jager R., Mieler, W. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
British Journal of Ophthalmology. 2008 Apr;92(4):584.
Hariprasad S., Mieler W., Grassi M., Green J., Jager R., Miller L. Vision-related quality of life in patients with diabetic macular oedema.
British Journal of Ophthalmology. 2008 Jan;92(1):89-92. Epub 2007 Jun 21.
Shukla D., Aiello L., Kolluru C., Baddela S., Jager R., Kim R. Relation of optical coherence tomography and unusual angiographic leakage patterns in central serous chorioretinopathy.
Eye. 2007 Apr 20.
Shukla D., Dhoble P., Jager R., Aiello L.P., Ramasamy K. Closure of macular hole following vitrectomy for diabetic tractional macular detachment.
Eye. 2006 Dec;20(12):1386-8.
Singh, R., Jager, R., Alfaro, V., Puliafito, C. The Use of Optical Coherence Tomography in the Diagnosis and Assessment of AMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.
Wirostko, W., Jager, R., Singh, R., Kiernan, D., Mieler, W. Intraocular Foreign Bodies.
In Modern Management of Ocular Trauma, 2006.
Alfaro, D., Loethen, M., Jager, R., Kim, R. Ranibizumab (Lucentis™) for ARMD.
In Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006.
Agurto-Rivera R., Diaz-Rubio J., Torres-Bernal L., Macky T., Colina-Luquez J., Papa-Oliva G., Jager R,, Martinez-Jardon S., Fromow-Guerra J., Quiroz-Mercado H. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study.
BMC Ophthalmology. 2005 Nov 25;5:27.
Jager, R., Timothy, N., Coney, J., Katalinic, P., Cavicchi, R., Cavallerano, J., Aiello, L. Congenital Retinal Macrovessel.
Retina. 2005 Jun;25(4):538-540.
Jager R., Aiello, L., Patel S., Cunningham, E. Risks of Intravitreous Injection: A Comprehensive Review.
Retina. 2004 Oct;24(5):676-98.
Shahinian, L., Jain, S., Jager, R., et al. Dilute Topical Proparacaine for Pain Relief after Photorefractive Keratectomy.
Ophthalmology 1997; 104: 1327-1332.
Heymann, J., Jager, R., Subramaniam, S. Expression of Bacteriorhodopsin in Sf9 and COS-1 Cells.
Journal of Biomembranes and Bioenergetics 1997; 29: 55-59.
Jager, R., Chen, F. Musculoskeletal Photodiagnosis: Hereditary Multiple Exostoses.
Journal of Musculoskeletal Medicine 1998; 15(6): 63-64.
Presentations
Bhavsar A, Williams D, Jager RD. Intravitreal Injections: Sound Technique and Risk Reduction. Instructional Course. 2012 American Society of Retinal Specialists Annual Meeting.
Agarwal K, Bhatt HK, Sheth VS, Jager RD. Combination Therapy of Intravitreal Bevacizumab and Focal NAVILAS Laser in the Treatment of Macular Edema due to Branch Retinal Vein Occlusion. Poster Presentation. 2012 American Society of Retinal Specialists Annual Meeting.
Afshar A, Amara M, Grandhe S, Jager R. Focal Laser Treatment for Diabetic Macular Edema with the NAVILAS Navigated Laser Photocoagulation System. American Society of Retinal Specialists. Poster Presentation. 2011 Annual Meeting.
Agarwal K, Patel R, Jager R. Macular Schisis Following Indocyanine Green-Assisted Internal Limiting Membrane Peel for Epiretinal Membrane Surgery. ARVO 2011
Afshar A, Patel R, Jager R. Outcomes of Focal Laser Treatment for Diabetic Macular Edema with the NAVILAS Navigated Laser Photocoagulation System. ARVO 2011
Jager R, Miller J, Mieler W, Bressler N, Lim J, Cousins S. Age-related Macular Degeneration – Program Chair of the Symposium at the American Academy of Ophthalmology Annual Meeting in Chicago, 2010.
J. J. Chen, V. Eulo, Y. Huang, J. Rehman, S. M. Hariprasad, R. D. Jager, V. Sheth, D. L. Nicolae, Y. A. Lussier, and M. A. Grassi Study of Genetic Expression in Diabetic Retinopathy Reveals Unique Molecular Fingerprint ARVO Meeting ARVO 2010
R. M. Grutsch, D. F. Kiernan, R. D. Jager, and M. A. Saidel Demographic and Clinical Features of Anterior Uveitis in Female Patients at a University Ophthalmology Center in Chicago ARVO 2009.
D. F. Kiernan, S. M. Hariprasad, R. Singh, R. D. Jager, and W. F. Mieler The Association of Daily Anticoagulant Use and Intraocular Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration ARVO Meeting Abstracts April 11, 2009 50:3499
G. J. Burrell, S. M. Hariprasad, W. F. Mieler, and R. D. Jager Improvement in Visual Quality of Life After Traditional and Microincisional Vitrectomy Surgery ARVO 2008
A. J. Dave, A. Gabrielian, R. Lin, T. Lin, S. Hariprasad, R. Jager, J. Rago, J. Ernest, and V. Arun A Comparison of Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) in The Diagnosis and Assessment of Diabetic Macular Edema ARVO 2008
B. K. Williams, Jr., D. F. Kiernan, R. D. Jager, R. Lin, and W. F. Mieler The Effect of Internal Limiting Membrane Peel During Epiretinal Membrane Removal on Visual Acuity and Recurrence Rate in Diabetic and Non-Diabetic Eyes ARVO 2008
K. Grant-Acquah, D. F. Kiernan, R. D. Jager, and W. F. Mieler Intraoperative Use of Kenalog for Epiretinal Membrane Removal Is Associated With Improved Visual Outcomes and Decreased Membrane Recurrence ARVO 2008
R. Singh, A. P. Singh, A. Flaum, K. Grant-Acquah, D. Kiernan, N. James, W. Mieler, and R. D. Jager Comparative Transatlantic Survey of Patient Knowledge and Awareness of Hypertension and Its Effects on Eye Disease ARVO 2008
Johnson, V., Hariprasad, S., Grassi, M., Green, J., Jager, R., Mieler, W. The Impact of Diabetic Retinopathy on Vision-Related Quality of Life Ophthalmology. Poster presentation at the 2007 ARVO Annual Meeting.
Albin, S., Benevento, J., Chang, J., Jager, R. Diabetic Retinopathy Knowledge in University Clinic Patients. Poster presentation at the 2007 ARVO Annual Meeting.
Mazzulla, D., Hariprasad, S., Mojica, G., Radhakrishnan, C., Jager, R., Mieler, W. Short-Term Intraocular Trends Following Intravitreal Injection of Bevacizumab (Avastin). Poster presentation at the 2007 ARVO Annual Meeting.
Belsare, G., Hariprasad, S., Jager, R., Mazzulla, D., Mieler, W.. Effects on Visual Acuity and OCT Following Older Generation AMD Treatment With Subsequent Lucentis or Avastin Intravitreal Injections. Poster presentation at the 2007 ARVO Annual Meeting.
Miller, L., Mojica, G., Hariprasad, S., Mieler, W., Grassi, M., Green, J., Jager, R. Vision-Related Quality of Life in Patients With Diabetic Macular Edema. Poster presentation at the 2007 ARVO Annual Meeting.
Jager R., Aiello, L.P., Patel S.C., Cunningham, E.T. Complications of Intravitreal Injections: An evidence-based review. Paper presentation at the 2004 American Society of Retinal Specialists Annual Meeting.
Jager, R., Timothy, N., Coney, J., Keenan, H., Arrigg, P., Aiello, L.P. Endophthalmitis as a Complication of Intravitreal Injection: A Systematic Review. Poster presentation at the 2004 ARVO Annual Meeting.
Coney, J., Brathwaite, C., Jager, R., Doria, A., Timothy, N., Aiello, L.P. Clinical Characteristics of Complications in Patients with 50 or More Years of Type 1 Diabetes Mellitus. Poster presentation at the 2004 ARVO Annual Meeting.
Jager, R., Rubin, M., Albanis, C., et al. Rates of Posterior Capsular Rupture and Vitreous Loss During Phacoemulsification in the Presence or Absence of Diabetes and Hypertension. Poster presentation at the 2002 ARVO Annual Meeting.
Rubin, M., Goins, K., Jager, R., Albanis, C., Dwyer, M., Ernest, J. Comparison of Phacoemulsification Complication Rates in a University Setting Using Venturi and Peristaltic Machines. Poster presentation at the ARVO 2002 Annual Meeting.
Jager, R., Jain, S., et al. The Effect of Topical Dilute Proparacaine on Relief of Postoperative PRK Pain. Poster presentation at the 1996 ARVO Annual Meeting.
Other
Books
Sheth, V., Marcet, M., Bhatt, H., Chiranand, P., Lamkin, J., Jager, R. The Massachusetts Eye & Ear Infirmary Review Manual for Ophthalmology, 4th Edition. Lippincott, Williams & Wilkins, 2011 (ISBN: 1451111363)
Jager, R., Lamkin, J. The Massachusetts Eye & Ear Infirmary Review Manual for Ophthalmology, 3rd Edition. Lippincott, Williams & Wilkins, 2006 (ISBN: 0781758130)
Alfaro, V., Liggett, P., Mieler, W., Quiroz-Mercado, H., Jager, R., Tano, Y. Age Related Macular Degeneration: A Comprehensive Text. Lippincott, Williams & Wilkins, 2006 (ISBN: 0781738997)
Jager, R., Ortiz, R. In the Company of Giants: Candid Conversations with the Visionaries of the Digital World. McGraw-Hill, 1997 (ISBN: 0-07-03294-6)
Study Experience (For Which Was A Principal Investigator or Sub Investigator)
Genentech/DME Protocol GR40398 (RHINE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema
Genentech/wAMD Protocol GR40844 (LUCERNE)
A Phase II, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration
Genentech/GA Protocol GR40973 (GAllego)
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Evidence of Activity of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Ionis/GA Protocol ISIS 696844-CS5
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Gyroscope/GA Protocol GTSCOPE
A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Genentech/ DME Protocol BP41321 (Canberra)
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-Naive Diabetic Retinopathy
Regeneron/ wAMD Protocol VGFTe-HD-AMD-1905 (Candela)
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
Genentech/ wAMD Protocol GR40548 (Archway)
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Genentech/ DME Protocol GR40550 (PAGODA)
A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema
Genentech/ DR Protocol GR41675 (Pavillion)
A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy
Chengdu Kanghong/ wAMD Protocol KHB-1801 (PANDA)
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration
GrayBug Vision/ wAMD Protocol GBV102-002 (Altissimo)
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration
Outlook/ wAMD Protocol ONS-5010-002
A Clinical Effectiveness, Multicenter, Randomized, Double-Masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Novartis/ DME Protocol CRTH258B2305 (Kingfisher)
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Every 4 Weeks Versus Aflibercept Every 4 Weeks in Adult Patients with Visual Impairments due to Diabetic Macular Edema
Clearside/ RVO Protocol CLS-1003-302 (Topaz)
A Randomized, Masked, controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal Anti-VEGF in Subjects with Retinal Vein Occlusion
SalutarisMD/ wAMD Protocol SMD-201601
A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-Related Macular Degeneration
DRCR/ CI-DME Protocol AC
A Randomized Trial of Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema.
Aerpio/ NPDR Protocol AKB-9778-CI-5001
Phase 2 Double-Masked, Placebo-Controlled Study to access the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy
Regeneron/ NPDR Protocol VGFTe-OD-1411
Phase 3, Double-Masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe non-proliferative diabetic retinopathy
Allergan/ wAMD Protocol 150998-005/150998-006 (Cedar/Sequoia)
Safety and Efficacy of Aflibercept Pegol (AGN-150998) in patients with Neovascular Age-related Macular Degeneration
Genentech/ GA Protocol GX29176 (Chroma)
Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-related Macular Degeneration
Tyrogenex/ wAMD Protocol X82-OPH-201
A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority study of X-82 plus prn IVT Anti-VEGF compared to prn IVT Anti-VEGF monotherapy in Neovascular AMD
Alimera Science/ DME Protocol M-01-15-004 (Iluvien)
Phase 4 safety study of IOP signals in patients treated with Iluvien (Fluocinolone Acetonide Intravitreal Implant) 0.19mg
Genentech/ DME Protocol BP30099 (Boulevard)
A Multi-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Diabetic Macular Edema.
Regeneron/ wAMD Protocol R910-3-AMD-1517
A Randomized, Double-Masked, Active-Controlled Phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Neovascular Age-related Macular Degeneration
Regeneron/ wAMD Protocol R2176-3-AMD-1417
Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with Neovascular Age-related Macular Degeneration
Opthotech/ wAMD Protocol OPH1006
Effect of Anti-VEGF agents administered on a quarterly maintenance regimen in subjects with Neovascular AMD receiving Anti-PDGF Therapy: An 18 month Phase 2a Open Label, Randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)
Opthotech/ wAMD Protocol OPH1005
OPH1005B- Sub-Retinal Fibrosis in Neovascular AMD: 24 month Phase 2A Open Label safety study of Fovista (Anti-Pegylated Aptamer) regimen administered in combination with Anti-VEGF Therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy
Opthotech/ wAMD Protocol OPH1004B
Phase 3 Randomized, Double-Masked, Controlled trial to establish the safety and efficacy of intravitreous administration of Fovista (Anti-PDGF-B Pegylated Aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea Monotherapy in subjects with subfoveal Neovascular Age-related Macular Degeneration
DRCE/ CI-DME Protocol V
Treatment for Center-Involved Diabetic Macular Edema in eyes with very good visual acuity
Alcon/ wAMD Protocol LHA510-2201 (Alcon)
A Randomized, Double-Masked, Vehicle-Controlled, Proof-of-Concept study for topically delivered LHA510 as a maintenance therapy.
Thrombogenics/ Vitreomacular Adhesion/Vitreomacular Traction Protocol ORBIT
A Multicenter, prospective observational study assessing the clinical outcomes and safety of patients receiving JETREA® in a real-world setting for the treatment of symptomatic VMA/VMT following standard of care from US retina clinics.
ALCON / ARRT Protocol C-02-60
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients (Enrolled in Study “A” or Study “B”) at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration
ALIMERA / FAME
A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 micrograms/day and ASI-001B 0.2 micrograms/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema
ALIMERA / FAME-Extension
An open label, multi-center extension study of the safety and utility of the new inserter of ILUVIEN (Fluocinolone Acetonide Intrvitreal Insert) 0.19mg and the safety of ILUVIEN in subjects with diabetic macular edema.
ALLERGAN / RVO
A Six-Month, Phase III, Multicenter, Masked, Randomized, Sham-Controlled Trial (With Six-Month Open Label Extension) to Assess the Safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.
ALLERGAN / DME Protocol AGN206207-011-01
A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema.
FOVEA PHARMACEUTICALS / FOV2304 (Fovea)
A 6 month ,phase II, double-masked, multicenter, randomized, placebo-controlled, parallel group study to assess the safety and efficacy of topical adminitration of two concentrations of FOV2304 (1% and 2%) twice daily for the treatment of center-involving clinically significant Macular Edema associated with Diabetic Retinopathy.
GENENTECH / FVF4579g (HARBOR)
A Phase III, Double-Masked, Multicenter, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neoascular Age-Related Macular Degeneration
GENENTECH / FVF4967g (SHORE)
A multicenter randomized study evaluating dosing regimens for treatment with intravitreal ranibizamab injections in subject with macular edema following retinal vien occlusion.
NEI|DRCR / SCORE
A Randomized Trial to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema Associated with Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion
REGENERON / Protocol VGFT-OD-0508
A Randomized Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration Clinical Evaluation of Anti-Angiogenesis in the Retina Intravitreal Trial AMD Phase 2 (CLEAR-IT AMD-2)
REGENERON / VEGF-TRAP 0502
An Exploratory Study of the Safety, Tolerability and Biological Effect of Intravitreal Administration of VEGF Trap in Patients with Neovascular Age- Related Macular Degeneration (VGFT-OD-0502)